Phase III IMpassion130 Study Showed Genentechs TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer

First Phase III immunotherapy study to demonstrate a statistically significant progressionfree survival PFS improvement in intentiontotreat ITT and PDL1 positive firstline metastatic triple negative breast cancer TNBC populations ...